NASDAQ : EVO
Evotec SE — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Germany
Last price 1.58 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 581.45M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 559.29M |
| Enterprise Value | 570.76M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 177.67M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 30.42% |
| Float | 147.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.68 |
| Forward PS | 0.78 |
| PB Ratio | 0.74 |
| P/TBV Ratio | 1.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.33 |
| Quick Ratio | 2.02 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -26.08% |
| Return on Assets (ROA) | -5.39% |
| Return on Invested Capital (ROIC) | -22.13% |
| Return on Capital Employed (ROCE) | -11.56% |
| Weighted Average Cost of Capital (WACC) | 5.69% |
| Revenue Per Employee | $183,697 |
| Profits Per Employee | -$50,464 |
| Employee Count | 4,461 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 17.96 |
Taxes
| Measure | Value |
|---|
| Income Tax | 15.14M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -63.13% |
| 50-Day Moving Average | 1.65 |
| 200-Day Moving Average | 2.52 |
| Relative Strength Index (RSI) | 47.22 |
| Average Volume (20 Days) | 106,675 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 76,498 |
| Short Previous Month | 22,066 |
| Short % of Shares Out | 0.02% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.41 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 819.47M |
| Gross Profit | 69.36M |
| Operating Income | -166.64M |
| Pretax Income | -209.98M |
| Net Income | -225.12M |
| EBITDA | -83.61M |
| EBIT | -166.64M |
| Loss Per Share | -$0.62 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 531.92M |
| Total Debt | 543.66M |
| Net Cash | -11.74M |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | 760.40M |
| Book Value Per Share | 4.28 |
| Working Capital | 475.75M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -128.33M |
| Capital Expenditures | -53.76M |
| Depreciation & Amortization | 81.08M |
| Net Borrowing | -18.94M |
| Free Cash Flow | -182.08M |
| FCF Per Share | -$1.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | 8.46% |
| Operating Margin | -20.33% |
| Pretax Margin | -25.62% |
| Profit Margin | -27.47% |
| EBITDA Margin | -10.20% |
| EBIT Margin | -20.33% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | -40.47% |
| FCF Yield | -32.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.23 |
| Price Target Difference | 176.21% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -0.15% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 20, 2021 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.3 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |